Seeking Alpha

GlaxoSmithKline's (GSK +0.1%) lung treatment Relovair proved successful in two six-month phase...

GlaxoSmithKline's (GSK +0.1%) lung treatment Relovair proved successful in two six-month phase III trials. GSK and partner Theravance (THRX -1.6%) hope Relovair will generate billions of dollars, but will wait for results from larger 12-month studies before filing for approval. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs